azacitidine and apr-246

azacitidine has been researched along with apr-246 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	4 (100.00)	2.80

Authors

Authors	Studies
Sallman, DA	1
Ades, L; Attalah, H; Berthon, C; Bève, B; Carpentier, AF; Chermat, F; Chevret, S; Cluzeau, T; Cuzzubbo, S; Fenaux, P; Komrokji, R; Lehmann-Che, J; Loschi, M; Madelaine, I; Miekoutima, E; Peterlin, P; Quesnel, B; Raffoux, E; Rahmé, R; Rauzy, OB; Recher, C; Sallman, DA; Sebert, M; Stamatoullas, A; Walter-Petrich, A; Willems, L	1
Cassinat, B; Diawara, Y; Fenaux, P; Giraudier, S; Maslah, N; Sebert, M	1
Altman, JK; Attar, EC; Fathi, AT; Garcia-Manero, G; Goldberg, AD; Hickman, DK; Kanagal-Shamanna, R; Kantarjian, H; Komrokji, R; Lancet, J; Miller, C; Odenike, O; Roboz, GJ; Sallman, DA; Sweet, K; Wennborg, A; Winer, ES	1

Trials

2 trial(s) available for azacitidine and apr-246

Article	Year
Eprenetapopt Plus Azacitidine in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 05-10, Volume: 39, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53	2021
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. The Lancet. Haematology, 2023, Volume: 10, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Protein p53	2023

Other Studies

2 other study(ies) available for azacitidine and apr-246

Article	Year
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in Haematologica, 2020, Volume: 105, Issue:6 Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53	2020
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients. British journal of haematology, 2021, Volume: 194, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Treatment Outcome; Tumor Cells, Cultured	2021

Article

Year

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in

Haematologica, 2020, Volume: 105, Issue:6

Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53

2020

In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.

British journal of haematology, 2021, Volume: 194, Issue:4

Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Treatment Outcome; Tumor Cells, Cultured

2021